Cigarette smoking is the leading cause of preventable death in the US and it disproportionally affects individuals with mental and substance use disorders. Methamphetamine (MA) use in particular, is accompanied by high rates of comorbid tobacco smoking. Previous research has shown that the combination of naltrexone and oral bupropion (NTX-BUP) improves smoking cessation outcomes in non-MA-using populations. The ADAPT-2 trial, a NIDA Clinical Trials Network study in which CBAM participated, proved that NTX-BUP successfully reduced MA use, but researchers looking more closely at the data also found that NTX-BUP was associated with significant reductions in self-reported cigarette smoking for those participants in the trial who smoked.


To read the article in its entirety, click here.


CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illnesses, especially in communities with health disparities. As part of the UCLA Department of Family Medicine, CBAM works at the intersection of academia and community with a focus on treating addictions and preventing the spread of HIV.

© The UCLA Center for Behavioral & Addiction Medicine (CBAM). All Rights Reserved.